ASCO 2023: Radiotherapy may not be necessary after chemoimmunotherapy for primary mediastinal B-cell lymphoma
Results from the largest prospective study of primary mediastinal B-cell lymphoma show that radiation therapy…
Browsing: chemoimmunotherapy
EHA 2022: Improved progression-free survival is achievable using targeted therapy combinations with venetoclax in fit patients with treatment-naïve chronic lymphocytic leukaemia
Chemoimmunotherapy (CIT) is still standard treatment for patients with chronic lymphocytic leukaemia (CLL), particularly when…
EHA 2022: Adding targeted therapy to chemoimmunotherapy offers long-term benefits for patients with IGHV-mutated CLL
Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) is effective in treating patients with chronic lymphocytic leukaemia (CLL),…
Potential therapy may boost chemoimmunotherapy response in bladder cancer
Adding an anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of…
Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients
Survival rates increased about 20% for children with high-risk neuroblastoma enrolled in a St. Jude…
Protected: Immunotherapy combination now PBS listed for first-line treatment of metastatic non-squamous non-small cell lung cancer (1,2)
This content is password protected. To view it please enter your password below: Password:
ASH 2018: Ibrutinib outperforms chemoimmunotherapy in older patients with chronic lymphocytic leukaemia
A new study presented at ASH 2018 shows older patients with chronic lymphocytic leukaemia (CLL) have a…